Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06771219 · ClinicalTrials.gov registry record · Phase 1
SLV-154 Treatment of Metastatic Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Solve Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 9
- Study locations
NCT06771219 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Solve Therapeutics. The registered enrollment target is 70 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT06771219, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Solve Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
Conditions Studied
Interventions
- DRUG SLV-154
Study Locations (9)
Texas
- MD Anderson Cancer Center - Houston
- Oncology Consultants - Houston
- Mays Cancer Center; University of Texas Health San Antonio - San Antonio
Washington
- University of Washington / Fred Hutchinson Cancer Center - Seattle
- Northwest Medical Specialties, PLLC - Tacoma
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Missouri
- Washington University - St Louis
New Jersey
- Astera Cancer Care - East Brunswick
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06771219
The ClinicalTrials.gov registry entry for NCT06771219 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Solve Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which SLV-154 is the first listed.
NCT06771219 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Texas, Washington, California.
Frequently Asked Questions
What is clinical trial NCT06771219 about?
NCT06771219 is a clinical study titled "SLV-154 Treatment of Metastatic Solid Tumors". This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
What is the current status of trial NCT06771219?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2025-05-14. Estimated completion is 2027-04.
What conditions does trial NCT06771219 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Sarcoma, NSCLC, Thyroid Cancer.
What interventions are being tested in trial NCT06771219?
The interventions under investigation include: SLV-154 (DRUG).
Who is sponsoring clinical trial NCT06771219?
This trial is sponsored by Solve Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06771219 being conducted?
This trial has 9 study locations across California, Missouri, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.